Abstract 1152P
Background
Somatostatin-receptor (SSTR)-targeted-PET/CT is widely used for diagnosis and disease monitoring of pheochromocytoma / paraganglioma (PPGLs). The aim of this study was to assess the potential of the novel SSTR-targeted tracer [18F]-SiTATE in diagnosing PPGLs by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type.
Methods
All patients with histologically confirmed PPGL presenting for [18F]-SiTATE-PET/CT at LMU Klinikum between 10/2020 and 02/2024 as well as hormonal laboratory analysis of both plasma and 24-hour urine samples within up to 100 days were included. Metabolic tumor volume (MTV) was assessed using a threshold of mean standard uptake value (SUVmean) of 5.0. Total lesion uptake (TLU) was assessed with SUVmean x MTV. Correlation was tested using spearmanś rank correlation test.
Results
34/39 patients (median age: 55, range: 5-83) were included in this study. 5 patients with cervical PGL were excluded. 21 patients had metastatic disease. There was a moderate correlation between TLU and MTV and urinary dopamine (r=0.50-0.51, p<0.05) as well as norepinephrine (r=0.50-0.54, p<0.05). TLU and MTV correlated moderately with serum chromogranin-A levels (r= 0.60, p<0.01, respectively). A moderate correlation was determined between TLU and MTV with plasma normetaphrine and 3-Methoxytyramine (r=0.52-0.56, p<0.01).
Conclusions
MTV and TLU measured with [18F]-SiTATE-PET/CT correlate well with the tumor marker chromogranin-A in serum and with particular biomarkers of the catecholamine pathway in urine and plasma, reflecting metabolic tumor activity. Within the limits imposed by the relatively small cohort, our results suggest that TLU in [18F]-SiTATE-PET/CT could be used as imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1427P - Predicting overall survival and prognostic indicator genes in esophagogastric cancer patients using machine learning and bioinformatics analysis
Presenter: Nguyen-Kieu Viet-Nhi
Session: Poster session 17
1428P - Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study
Presenter: Hollie Clements
Session: Poster session 17
1429P - Differences in esophageal cancer incidence and survival by race/ethnicity: A SEER analysis
Presenter: Ashwin Kulshrestha
Session: Poster session 17
1430P - Impact of menadione supplementation in the treatment of patients with metastatic gastric cancer: A randomized phase II clinical trial
Presenter: Francisco Cezar Moraes
Session: Poster session 17
1431P - Assessing pathological complete response to neoadjuvant chemotherapy combined with immunotherapy in esophageal squamous cell carcinoma: A deep learning approach with voxel-level radiomics
Presenter: Yongling Ji
Session: Poster session 17
1432P - Safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: A prospective multicenter trial (CLASS-03a)
Presenter: Kun Yang
Session: Poster session 17